Filibuvir

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameFilibuvir
Drug Alias Namefilibuvirum菲利布韦非利布韦PF-868554PF-00868554
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis, ChronicHepatitisHepatitis C, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsHepatitis, ChronicHepatitisHepatitis C, Chronic +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG